These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37986199)

  • 1. Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.
    Ghaempanah F; Nikouei M; Cheraghi M; Jahangiri A; Moradi Y
    J Pharm Policy Pract; 2023 Nov; 16(1):151. PubMed ID: 37986199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Assi R; Evrenoglou T; Buckley BS; Henschke N; Probyn K; Riveros C; Davidson M; Graña C; Bonnet H; Jarde A; Ávila C; Nejstgaard CH; Menon S; Ferrand G; Kapp P; Breuer C; Schmucker C; Sguassero Y; Nguyen TV; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013881. PubMed ID: 37260086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
    Juul S; Nielsen EE; Feinberg J; Siddiqui F; Jørgensen CK; Barot E; Holgersson J; Nielsen N; Bentzer P; Veroniki AA; Thabane L; Bu F; Klingenberg S; Gluud C; Jakobsen JC
    PLoS One; 2021; 16(3):e0248132. PubMed ID: 33705495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
    Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
    Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.
    Kotak S; Khatri M; Malik M; Malik M; Hassan W; Amjad A; Malik F; Hassan H; Ahmed J; Zafar M
    Cureus; 2020 Oct; 12(10):e10869. PubMed ID: 33178522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Boppana TK; Mittal S; Madan K; Mohan A; Hadda V; Guleria R
    Monaldi Arch Chest Dis; 2022 Feb; 92(4):. PubMed ID: 35130679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
    Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
    Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
    Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
    Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

  • 14. Physical interventions to interrupt or reduce the spread of respiratory viruses.
    Jefferson T; Del Mar CB; Dooley L; Ferroni E; Al-Ansary LA; Bawazeer GA; van Driel ML; Jones MA; Thorning S; Beller EM; Clark J; Hoffmann TC; Glasziou PP; Conly JM
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD006207. PubMed ID: 33215698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early versus late tracheostomy in critically ill COVID-19 patients.
    Szafran A; Dahms K; Ansems K; Skoetz N; Monsef I; Breuer T; Benstoem C
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015532. PubMed ID: 37982427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise-based cardiac rehabilitation for coronary heart disease.
    Anderson L; Thompson DR; Oldridge N; Zwisler AD; Rees K; Martin N; Taylor RS
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD001800. PubMed ID: 26730878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
    Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
    Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
    Sarfraz A; Sarfraz Z; Sarfraz M; Aftab H; Pervaiz Z
    Turk J Med Sci; 2021 Jun; 51(3):890-897. PubMed ID: 33244947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.